The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1335
ISSUE1335
April 5, 2010
Liraglutide (Victoza) for Type 2 Diabetes
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Liraglutide (Victoza) for Type 2 Diabetes
April 5, 2010 (Issue: 1335)
Liraglutide (Victoza – Novo Nordisk), a glucagon-like peptide-1 (GLP-1) receptor agonist given by subcutaneous
injection, has been approved by the FDA for treatment of patients with type 2 diabetes. It can be used alone or in addition to oral...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.